移植前缓解欠佳的多发性骨髓瘤患者接受自体移植的结局
该回顾性单中心分析纳入2005至2021年间接受 upfront 自体造血干细胞移植、移植前缓解不足非常好的部分缓解(<VGPR)的新诊断多发性骨髓瘤(NDMM)患者1109例,全队列中位无进展生存期(PFS)38.6个月(95%CI 35.9-41.9),中位总生存期(OS)103.8个月(95%CI 96.4-113.2);移植后维持治疗和移植后最佳疗效达完全缓解(CR)与更优的PFS和OS相关。
要点
- 移植前<VGPR的NDMM患者接受自体移植后中位PFS为38.6个月,中位OS为103.8个月。
- 高危细胞遗传学异常(HRCA)患者中位PFS为24.8个月,中位OS为69.9个月。
- 移植后维持治疗与更优PFS(HR 0.75,p=0.001)和OS(HR 0.75,p=0.008)相关。
核心结论
- 移植前缓解<VGPR的NDMM患者接受upfront自体移植后中位PFS超过3年、中位OS超过8年,移植后维持治疗进一步改善生存结局。
研究设计与样本
- 回顾性、单中心分析,纳入2005至2021年间接受upfront自体造血干细胞移植、移植前缓解<VGPR的NDMM患者1109例,主要终点为PFS和OS。
主要发现
- 全队列中位PFS为38.6个月(95%CI 35.9-41.9),中位OS为103.8个月(95%CI 96.4-113.2)。
- 高危细胞遗传学异常(HRCA)患者中位PFS为24.8个月,中位OS为69.9个月。
- 多变量分析中,移植后维持治疗与更优PFS相关(HR 0.75,p=0.001),与更优OS相关(HR 0.75,p=0.008)。
- 移植后最佳疗效达完全缓解(CR)与更优PFS相关(HR 0.60,p<0.001),与更优OS相关(HR 0.51,p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are scarce data in the literature focusing on newly diagnosed multiple myeloma (NDMM) patients who undergo autologous haematopoietic cell transplantation (autoHCT) after achieving suboptimal response to induction. To address this, we performed a retrospective, single-centre analysis of patients with NDMM who underwent upfront autoHCT between 2005 and 2021 with a pretransplant response of less than very good partial response (<VGPR). Primary outcomes were progression-free survival (PFS) and overall survival (OS). 1109 patients were included in our analysis. Median PFS and OS for the entire cohort were 38.6 (95% confidence interval [CI], 35.9-41.9) months and 103.8 (95% CI, 96.4-113.2) months, respectively. Patients with high-risk cytogenetic abnormalities (HRCA) had a median PFS and OS of 24.8 months and 69.9 months respectively. In multivariable analysis, the use of post-transplant maintenance (hazard ratio [HR] 0.75, p = 0.001 and HR 0.75, p = 0.008) and achieving complete response (CR) at best post-transplant response (HR 0.60, p < 0.001 and HR 0.51, p < 0.001) were associated with superior PFS and OS respectively. In conclusion, NDMM patients who received upfront autoHCT with a pretransplant response of <VGPR had a median PFS of >3 years and median OS of >8 years. Post-transplant maintenance further improved survival outcomes.
引用
- Pasvolsky O, Abid MB, Milton DR, et al. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. Br J Haematol. 2025. PMID: 40159289. doi:10.1111/bjh.20062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。